GlyphAllo (allopregnanolone prodrug) vs HS-10353

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: GABA-A receptor · full Major Depressive Disorder pipeline

GlyphAllo (allopregnanolone prodrug) · SPT-300

Developed by Seaport Therapeutics and partners

Phase 2 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT07065240 (registry estimate)

No aligned efficacy figure on record for this race.

HS-10353

Developed by Hansoh Pharmaceutical Group

Phase 2 in Major Depressive Disordersmall molecule
Weak signal

NCT05195203 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Endpoints of the trial:AE,SAE". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Endpoints of the trial:AE,SAE (Baseline to end of follow-up (a maximum of 20 days)): Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses

Result source: NCT05195203

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGlyphAllo (allopregnanolone prodrug)HS-10353
MADRS, change (acute)—Not reported—Not reported
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

GlyphAllo (allopregnanolone prodrug)
—Not reported
HS-10353
—Not reported

CGI-S, change (acute)

GlyphAllo (allopregnanolone prodrug)
—Not reported
HS-10353
—Not reported

MADRS response

GlyphAllo (allopregnanolone prodrug)
—Not reported
HS-10353
—Not reported

MADRS remission

GlyphAllo (allopregnanolone prodrug)
—Not reported
HS-10353
—Not reported

Relapse (% of patients)

GlyphAllo (allopregnanolone prodrug)
—Not reported
HS-10353
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

GlyphAllo (allopregnanolone prodrug): no structured comparison results are available for Major Depressive Disorder.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HS-10353
Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses NCT05195203 · Phase 1 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GlyphAllo (allopregnanolone prodrug)'s landscape · HS-10353's landscape